CAC Score (Coronary Calcium): What Your Number Changes About Your Treatment

What the CAC Score Actually Measures

The coronary artery calcium (CAC) score is a number derived from a non-contrast CT scan of your chest, usually completed in under 15 minutes with no injections. The scanner detects calcium deposits within the walls of the coronary arteries and assigns each deposit a density and area score using the Agatston method. Those values are summed across all four major coronary vessels to produce your total CAC score.

Calcium in arterial walls is a marker of atherosclerotic plaque. Plaque itself begins as cholesterol-laden foam cells, but over years it mineralizes and becomes detectable on CT. A higher score means more calcified plaque, which generally correlates with a greater total plaque burden and a higher risk of a future heart attack or stroke.

Why This Matters More Than Cholesterol Alone

Standard risk calculators, such as the Pooled Cohort Equations, use age, sex, cholesterol, blood pressure, smoking, and diabetes to estimate your 10-year cardiovascular risk. They are useful but imperfect. Roughly 45% of people who have a first heart attack have cholesterol levels that would not have triggered a statin prescription under standard guidelines.

The CAC scan looks directly at your arteries. It shows whether atherosclerosis has actually started, regardless of what your blood numbers say. The Multi-Ethnic Study of Atherosclerosis (MESA) enrolled over 6,000 participants and demonstrated that a CAC score of 0 was associated with a 10-year cardiovascular event rate below 1%, even among individuals whose cholesterol-based risk score placed them in an intermediate-risk category.

How the Score Is Calculated and Reported

| Score Range | Category | Common Interpretation | |---|---|---| | 0 | No detectable calcification | Very low near-term risk | | 1-99 | Mild | Some plaque; risk depends on context | | 100-299 | Moderate | Statin therapy generally beneficial | | 300-399 | High | Aggressive risk management | | 400+ | Very high | Equivalent to known coronary artery disease |

Scores are also sometimes expressed as percentiles adjusted for age, sex, and ethnicity using the MESA CAC Reference Values, which is particularly useful when your raw score is low but your percentile is high for your demographic group.

How Women's CAC Scores Differ From Men's

Women are not simply smaller men with different hormones. The biology of coronary artery disease in women differs in timing, presentation, and trajectory, and the CAC score needs to be interpreted within that context.

The Estrogen-Protection Window

Premenopausal women with intact ovarian function have significantly lower CAC scores than age-matched men. Data from MESA showed that women's CAC scores lag men's by approximately 10 years across all ethnic groups. Estrogen supports endothelial function, reduces LDL oxidation, and has direct anti-inflammatory effects on vascular walls. This protection is real but not permanent.

The Menopause Inflection Point

The transition through perimenopause and into post-menopause accelerates CAC progression. A study published in Menopause found that women who underwent surgical menopause had significantly faster CAC progression than those who underwent natural menopause, and both groups progressed faster than premenopausal women of similar age. Estrogen loss removes the protective brake on plaque calcification.

This means a 55-year-old woman two years past her final menstrual period with a CAC score of 150 is in a different clinical situation than a 55-year-old man with the same score. Her score arrived earlier than expected for her sex. That acceleration itself is a risk signal.

PCOS and Early Vascular Aging

Women with polycystic ovary syndrome (PCOS) carry a metabolic risk profile, including insulin resistance, higher androgen levels, and dyslipidemia, that accelerates vascular aging. A 2016 systematic review in the European Journal of Endocrinology found significantly higher CAC scores in women with PCOS compared with controls, independent of BMI. If you have PCOS and are approaching 40, a CAC scan may provide earlier cardiovascular clarity than standard risk calculators.

Female Pattern Cardiovascular Disease

Women are more likely than men to develop plaque that is diffuse rather than focal, and to have microvascular disease that is not captured by CAC. A CAC of 0 is reassuring but does not rule out ischemia in women with typical anginal symptoms. This is one reason clinical context, not the score in isolation, drives management.

What a CAC Score of 0 Means for You

A score of 0 is genuinely good news. No calcified plaque is detectable. The MESA data showed a 10-year cardiovascular event rate of approximately 0.8% among individuals with a score of 0. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly states that a CAC of 0 may be used to defer statin therapy in patients whose 10-year risk estimate sits in the borderline (5-7.5%) or intermediate (7.5-20%) range and who prefer to avoid medication.

A score of 0 does not last forever. Calcification can develop as you age, particularly after menopause. Most guidelines suggest that if you scored 0 before 55, repeating the scan in 5 years is reasonable. After 65, even a 0 score warrants continued attention to lifestyle and traditional risk factors.

The WomanRx CAC-0 Decision Framework:

For a perimenopausal woman with borderline risk on the Pooled Cohort Equations and a CAC of 0, the conversation with her clinician should address four specific questions:

1. Has she started estrogen loss? (Menopause transition accelerates future CAC accumulation.)
2. Does she have PCOS or a history of hypertensive pregnancy disorders? (Both predict faster vascular aging.)
3. Does she have a family history of premature coronary disease in a first-degree female relative before age 65?
4. What is her C-reactive protein? (A CAC of 0 plus an elevated hsCRP still flags inflammatory vascular risk.)

If she answers yes to two or more of these, deferring statin therapy may still be appropriate, but the rescan interval should shorten to 3 years, not 5.

What a CAC Score Between 1 and 99 Means

Some plaque is present. The clinical response depends heavily on your total risk profile. The 2019 ACC/AHA guideline characterizes a score of 1-99 as a "risk-enhancer" that should tip the discussion toward statin initiation in someone who was already on the fence.

Statins in This Range

For a woman in this range, a moderate-intensity statin, such as atorvastatin 10-20 mg or rosuvastatin 5-10 mg, is typically the starting conversation. The JUPITER trial, which enrolled women with elevated hsCRP, demonstrated a 44% relative risk reduction in cardiovascular events with rosuvastatin 20 mg compared with placebo. Women made up 38% of JUPITER participants, which is a better representation than most earlier statin trials, though still not majority female.

Aspirin in This Range

Low-dose aspirin (81 mg) is no longer recommended for primary prevention in most adults, following the ASPREE trial. A CAC score of 1-99 alone does not restore aspirin's benefit. However, women with a CAC above 100 who have additional risk factors may be candidates for aspirin discussion with their provider.

Lifestyle Changes in This Range

A score in this range is modifiable at the margins through lifestyle. Smoking cessation is the single most powerful intervention; it reduces CAC progression by approximately 25% in active smokers who quit. A study in Arteriosclerosis, Thrombosis, and Vascular Biology confirmed that exercise-based interventions slow CAC progression, though they do not erase existing calcification.

What a CAC Score of 100 or Higher Means

A score of 100 or above places you in a category where cardiovascular event rates are high enough that statin therapy is appropriate for almost everyone, regardless of how the Pooled Cohort Equations scored you. The 2019 ACC/AHA guideline states: "If CAC is 100 Agatston units or greater, it is reasonable to initiate statin therapy."

Score 100-399

A high-intensity statin, atorvastatin 40-80 mg or rosuvastatin 20-40 mg, is typically warranted. Your clinician will also address:

• Blood pressure target (below 130/80 mmHg per 2017 ACC/AHA hypertension guidelines)
• HbA1c if not recently checked
• Sleep apnea screening (untreated apnea accelerates CAC progression)
• Anti-inflammatory lifestyle: Mediterranean-pattern diet, 150 minutes per week of moderate activity

Score 400 and Above

A score above 400 is treated clinically as the equivalent of established coronary artery disease. The ACC/AHA guideline recommends high-intensity statin therapy and a cardiology referral. Stress testing may be appropriate to look for inducible ischemia, even in the absence of symptoms. The annual cardiovascular event rate in this group approaches 3-4%.

For post-menopausal women in this range, hormone therapy decisions become more complex. The The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement notes that systemic estrogen therapy should generally be avoided in women with established or high-burden cardiovascular disease. A CAC above 400 warrants a careful, individualized conversation before initiating or continuing hormone therapy.

Can You Lower a CAC Score?

Existing calcification cannot be dissolved or removed. A score of 150 will not become 0 through medication or lifestyle changes. What you can modify is the rate of progression, total plaque stability, and your downstream event risk.

What Statins Actually Do to Plaque

Statins may paradoxically increase measured CAC scores in the first one to two years of treatment. This reflects plaque stabilization: soft, lipid-rich plaque mineralizes and becomes denser as statins reduce inflammation and stabilize the fibrous cap. A rising CAC score on a statin does not mean the statin is failing. A 2015 analysis in JACC confirmed that statin use is associated with faster CAC progression on CT but with lower rates of clinical cardiovascular events.

This counterintuitive finding confuses many patients. The calcium score is not a direct measure of plaque volume, and a denser, more calcified plaque is actually a more stable plaque.

Lifestyle Interventions With Evidence

• Mediterranean diet: Reduces LDL and inflammatory markers; associated with slowed plaque progression in the PREDIMED trial
• Aerobic exercise: 150 minutes per week of moderate-intensity activity is associated with slower CAC progression, based on MESA exercise data
• Smoking cessation: One of the few interventions that demonstrably slows CAC accumulation rate
• Blood pressure control: Hypertension independently predicts CAC progression; treating it to below 130/80 mmHg slows the process

What Does Not Work

Vitamin D supplementation, vitamin K2, and magnesium supplementation are frequently marketed as "coronary calcium reducers." No randomized controlled trial has demonstrated meaningful CAC regression with any of these agents in humans. The VITAL trial showed no significant cardiovascular benefit from vitamin D3 2000 IU daily over 5 years in a population of over 25,000 adults.

Hormone Therapy, Menopause, and the CAC Score

Menopausal hormone therapy (MHT) and its relationship to coronary disease is one of the most discussed topics in women's cardiovascular health. The CAC score gives us a concrete tool to individualize this decision.

The ELITE (Early vs. Late Intervention Trial with Estradiol) study showed that oral estradiol initiated within 6 years of menopause slowed CIMT (carotid intima-media thickness) progression compared with placebo, suggesting a cardiovascular benefit when started early. Subclinical atherosclerosis burden, which is what the CAC score captures, may be the key stratifier.

The Menopause Society 2022 Position Statement states: "For women who are within 10 years of menopause onset or are younger than 60 years of age, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms."

A woman who is 53, 2 years post-menopause, has bothersome hot flashes, and a CAC score of 0 sits in a favorable position for MHT initiation. A woman who is 68, 18 years post-menopause, with a CAC score of 380 and newly presenting hot flashes is in a very different risk category where MHT requires much more careful discussion with a NAMS-certified clinician.

Who Should Get a CAC Scan

The 2019 ACC/AHA Primary Prevention Guideline recommends considering a CAC scan for adults aged 40-75 who are in the borderline (5-7.5%) or intermediate (7.5-20%) 10-year risk range and where the statin decision is uncertain after a clinician-patient discussion.

Women-specific indications that raise the case for a CAC scan even at lower apparent risk include:

• History of preeclampsia or gestational hypertension (associated with a 2-fold increase in lifetime cardiovascular risk per ACOG Practice Bulletin)
• History of preterm delivery (associated with higher CAC scores in later life)
• Premature menopause before age 45
• PCOS with metabolic features
• Autoimmune conditions such as lupus or rheumatoid arthritis
• Family history of premature coronary disease in a first-degree female relative before age 65

The USPSTF has not issued a separate recommendation specifically for CAC screening in women, and this represents a genuine evidence gap. Most CAC outcome data in women comes from MESA and similar cohort studies, not from randomized trials with female-specific endpoints.

Who Should Not Get a CAC Scan

The scan is not appropriate if:

• You are pregnant (ionizing radiation; the scan is deferred until after delivery)
• You have already had a heart attack, stent, or coronary bypass surgery (you already have established cardiovascular disease and the decision zone question is moot)
• You are under 40 with no exceptional risk factors
• Your 10-year risk is already above 20% and statin therapy is clearly indicated regardless of CAC

Pregnancy, Lactation, and the CAC Scan

The coronary artery calcium scan uses ionizing radiation, typically 1-3 mSv depending on the scanner and protocol. This is a low dose compared with diagnostic cardiac catheterization, but it is not zero.

Pregnancy: The scan is contraindicated during pregnancy. Radiation exposure to a developing fetus, even at low doses, carries theoretical risk and no maternal benefit that cannot be deferred. If you had a CAC scan before pregnancy, that result remains clinically relevant for post-pregnancy cardiovascular risk counseling. A history of preeclampsia or gestational hypertension in the pregnancy that follows should prompt re-evaluation of cardiovascular risk when you are postpartum and planning your next preventive health visit.

Postpartum: There is no lactation contraindication to the CAC scan itself. The scan involves no contrast agent and no radioactive tracer. If you are breastfeeding and the clinical need for the scan is present, you do not need to interrupt breastfeeding before or after the procedure.

Contraception note: The CAC scan is not a medication and carries no teratogen risk beyond the radiation dose, which is low. No contraception requirement applies. However, women with high CAC scores who are discussing statin therapy should be counseled on statin teratogenicity before conception, as statins are FDA category X in pregnancy and must be stopped before attempting conception.

Reading Your Results: A Plain-Language Summary

Your CAC report will list a total Agatston score and may include a percentile for your age, sex, and race or ethnicity. Here is how to read it:

• Score 0: No calcified plaque detected. Very reassuring for near-term risk. Lifestyle remains important; recheck in 3-5 years depending on your menopause status and risk factors.
• Score 1-99: Mild plaque. Start a serious conversation about statins if you are in the intermediate-risk range on a standard calculator. Lifestyle changes are non-negotiable.
• Score 100-299: Moderate plaque. Statin therapy is appropriate for most women in this range. Blood pressure and blood sugar control are high priority.
• Score 300+: High plaque burden. High-intensity statin therapy, cardiology input, and close monitoring of all modifiable risk factors. Hormone therapy decisions need a specialist conversation.
• Above 75th percentile for your age and sex: Even a numerically low score carries more clinical weight if it is high relative to your demographic group.

The Menopause Society's 2022 Position Statement explicitly acknowledges that subclinical atherosclerosis assessment, including CAC scoring, should be part of the individualized cardiovascular risk evaluation before starting hormone therapy in peri- and post-menopausal women.

Your next step after receiving results is a structured conversation with your clinician covering your score, your percentile, your menopause status, any pregnancy history with hypertensive complications, and your preferences around medication. Bring this article if it helps frame those questions.